Overview

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Status:
Completed

Trial end date:
2018-01-22

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

Antidiarrheals
Eluxadoline
Loperamide